DNA detective work: can genes predict dangerous blood pressure spike from cancer drug?

NCT ID NCT02610413

Recruiting now Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines DNA from 354 breast cancer patients who took the drug bevacizumab. Some developed severe high blood pressure, while others did not. Researchers will compare their DNA to find genetic changes that might raise the risk of this side effect. The goal is to better understand who is at risk, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which patients are at risk for high blood pressure from bevacizumab, allowing safer treatment choices.
What could go wrong: This is an early exploratory study analyzing stored DNA samples, not testing a new treatment. It may not find clear genetic links, and any findings would need much more research before changing patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA

Contacts and locations

Locations

Eastern Cooperative Oncology Group
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.